Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 3, 2019Journal of Clinical OncologyOpen Access

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJohn K. LinThe University of Texas MD Anderson Cancer CenterLMLori MufflyStanford Health CareMSMichael A. SpinnerUniversity of California, San Francisco

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lin et al. (2019) studied this question.

synapsesocial.com/papers/6a10ff1563b25c787d9fe0eahttps://doi.org/10.1200/jco.18.02079
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia2003 · 455 citations
  2. 2Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses2016 · 3,120 citations
  3. 3Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma2018 · 51 citations
  4. 4Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in Non-VA and VA Populations2016 · 12 citations
  5. 5Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia2005 · 993 citations